126 related articles for article (PubMed ID: 19473378)
1. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management.
Zeppetella G
Eur J Cancer Care (Engl); 2009 Jul; 18(4):331-7. PubMed ID: 19473378
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough pain in cancer patients.
Zeppetella G
Clin Oncol (R Coll Radiol); 2011 Aug; 23(6):393-8. PubMed ID: 21227666
[TBL] [Abstract][Full Text] [Related]
3. Impact and management of breakthrough pain in cancer.
Zeppetella G
Curr Opin Support Palliat Care; 2009 Mar; 3(1):1-6. PubMed ID: 19365156
[TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
6. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
Mercadante S; Villari P; Ferrera P; Mangione S; Casuccio A
Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
8. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
Rhiner M; Palos G; Termini M
Clin J Oncol Nurs; 2004 Oct; 8(5):507-12. PubMed ID: 15515284
[TBL] [Abstract][Full Text] [Related]
9. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
10. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
11. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
Binhas M; Krakowski I; Marty J
Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
[TBL] [Abstract][Full Text] [Related]
12. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief.
Zeppetella G
J Pain Symptom Manage; 2008 May; 35(5):563-7. PubMed ID: 18258412
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
14. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
[TBL] [Abstract][Full Text] [Related]
15. The treatment of breakthrough pain.
McCarberg BH
Pain Med; 2007; 8 Suppl 1():S8-13. PubMed ID: 17280601
[TBL] [Abstract][Full Text] [Related]
16. Optimization of opioid therapy for preventing incident pain associated with bone metastases.
Mercadante S; Villari P; Ferrera P; Casuccio A
J Pain Symptom Manage; 2004 Nov; 28(5):505-10. PubMed ID: 15504626
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of pain in cancer with systemically administered opioids].
Enting RH; van der Rijt CC; Wilms EB; Lieverse PJ; de Wit R; Smitt PA
Ned Tijdschr Geneeskd; 2001 May; 145(20):950-4. PubMed ID: 11396259
[TBL] [Abstract][Full Text] [Related]
18. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; Mangione S
J Pain Symptom Manage; 2008 Mar; 35(3):307-13. PubMed ID: 18178368
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study.
Fisher K; Stiles C; Hagen NA
J Pain Symptom Manage; 2004 Dec; 28(6):619-25. PubMed ID: 15589088
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
